Abstract:ABSTRACT This work presents a multi-hurdle approach that addresses antimicrobial resistance by minimizing the selective pressure of antimicrobials using a novel colicinogenic–phage system. We have created two synthetic T7 phages (T7-E1 and T7-M) by inserting the gene of colicin E1 (Cea) or colicin M (Cma) into the genome of the T7 phage, thereby adding an additional colicin-based hurdle to the T7 lytic cycle. The colicin–phages' efficacy in suppressing the outgrowth of a T7-resistant sub-population within a mixed culture of Escherichia coli was demonstrated using a challenge matrix design under planktonic and structured conditions. When T7-resistant cells were present at 1% of the total planktonic population, T7-E1 delayed the outgrowth. At 0.1% resistance, T7-M delayed resistant outgrowth, whereas T7-E1 suppressed the resistant sub-population. When T7-E1 and T7-M were combined into a triple-hurdle treatment, the T7-E1/T7-M cocktail completely suppressed a mixed planktonic population of 50% resistance cell concentrations. In structured environments, the colicin–phage treatments formed clear and confluent plaque-like zones of clearing in the mixed populations of 50% resistant cells with a lawn density of 1 × 10 6 CFU/mL. Reducing the lawn density to 1 × 10 5 CFU/mL diminished the multi-hurdle treatments' effectiveness, as demonstrated by localized zones of clearing within turbid bacterial lawns, highlighting the relationship between bacterial lawn density and phage effectiveness in structured environments. Fluctuation assays revealed persistence as the predominant mechanism for overcoming the treatments by T7-sensitive E. coli . Results indicate that T7-M treatment significantly reduces persister formation compared to WT-T7, while T7-E1 unexpectedly increases persister formation significantly. This suggests a complex relationship between antimicrobial stress and persister formation. IMPORTANCE Antimicrobial resistance (AMR) poses a significant challenge in treating bacterial infections. To address this, we present a multi-hurdle approach that combines the power of different antimicrobials to target resistance. We have weaponized the natural predator of Escherichia coli , the T7-phage, by engineering it to produce toxins called colicins, resulting in a colicin–phage antimicrobial. This multi-hurdled approach aims to decrease resistance risk because survival requires different tactics to overcome the phage and colicin activity, thus adding a hurdle in a bacterium's pathway to resistance. In cases of pre-existing resistance, the colicin effectively controlled the sub-population resistant to the phage. When investigating the emergence of resistance, we discovered that antimicrobial persistence was the predominant survival strategy. These findings reveal an essential slice of the AMR pie by emphasizing bacterial survival tactics that are not based on resistance genes. By expanding our AMR lens to include persistence, we can more effectively address treatment failure.

The antiphage defense system CBASS controls resistance and enables killing by antifolate antibiotics in Vibrio cholerae

The Vibrio cholerae CBASS phage defence system modulates resistance and killing by antifolate antibiotics

Activation of a Vibrio cholerae CBASS anti-phage system by quorum sensing and folate depletion

Sporadic phage defense in epidemic Vibrio cholerae mediated by the toxin-antitoxin system DarTG is countered by a phage-encoded antitoxin mimic

The arms race between bacteria CBASS and bacteriophages

Reversible conjugation of a CBASS nucleotide cyclase regulates bacterial immune response to phage infection

A Vibrio cholerae Anti-Phage System Depletes Nicotinamide Adenine Dinucleotide to Restrict Virulent Bacteriophages

Mechanism of phage sensing and restriction by toxin-antitoxin-chaperone systems

Phage defence by deaminase-mediated depletion of deoxynucleotides in bacteria.

Decoupling the molecular versatility of aminoglycosides via drug or target modification enables community-wide antiphage defense

Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny

Phage defence system CBASS is regulated by a prokaryotic E2 enzyme that imitates the ubiquitin pathway

Resistance against aminoglycoside antibiotics via drug or target modification enables community-wide antiphage defense

A large-scale type I CBASS antiphage screen identifies the phage prohead protease as a key determinant of immune activation and evasion

Phage anti-CBASS and anti-Pycsar nucleases subvert bacterial immunity

The LAMP-CRISPR-Cas13a technique for detecting CBASS-mechanism of phage resistance in bacteria

Systematic functional assessment of antiphage systems in their native host

Assessment of resistance to colicinogenic synthetic phage antimicrobial system

An archaeal CBASS system eliminates viruses without killing the host cells

Regulation of anti-phage defense mechanisms by using cinnamaldehyde as a quorum sensing inhibitor

Diversified repertoire of phage resistance in and bidirectional steering effects impacting antibiotic susceptibility